Zhejiang AngLiKang Pharmaceutical CO.,LTD. (SHE:002940)
China · Delayed Price · Currency is CNY 34.17
-1.18 (-3.34%)
Apr 29, 2026, 3:04 PM CST
SHE:002940 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,425 | 1,513 | 1,621 | 1,560 | 1,375 |
Other Revenue | - | - | - | 8.09 | 5.48 |
| 1,425 | 1,513 | 1,621 | 1,568 | 1,380 | |
Revenue Growth (YoY) | -5.83% | -6.63% | 3.32% | 13.62% | 7.03% |
Cost of Revenue | 862.36 | 925.32 | 913.72 | 674.86 | 488.02 |
Gross Profit | 562.45 | 587.78 | 706.85 | 893.58 | 892.36 |
Selling, General & Admin | 251.37 | 274.01 | 396.04 | 631.65 | 671.11 |
Research & Development | 144.05 | 214.34 | 143.37 | 112.62 | 52.55 |
Other Operating Expenses | -36.06 | -18.66 | 5.33 | 8.56 | 14.8 |
Operating Expenses | 359.36 | 469.41 | 543.21 | 751.81 | 741.11 |
Operating Income | 203.09 | 118.37 | 163.64 | 141.77 | 151.25 |
Interest Expense | - | -16.6 | -14.17 | -6.39 | -0.37 |
Interest & Investment Income | - | 18.96 | 21.95 | 17.52 | 25.78 |
Currency Exchange Gain (Loss) | - | 7.21 | 2.44 | 1.27 | -0.58 |
Other Non Operating Income (Expenses) | -0.25 | -0.43 | -0.72 | -1.69 | -0.36 |
EBT Excluding Unusual Items | 202.84 | 127.51 | 173.13 | 152.48 | 175.72 |
Gain (Loss) on Sale of Investments | -17.68 | -5.69 | -1.7 | -2.96 | -9.05 |
Gain (Loss) on Sale of Assets | -0.03 | -0.01 | -0.04 | -0.39 | -0.59 |
Asset Writedown | -4.85 | -2.93 | -1.96 | -2.18 | - |
Other Unusual Items | - | 39.49 | 37.77 | - | 6.56 |
Pretax Income | 180.28 | 158.37 | 207.2 | 146.94 | 172.65 |
Income Tax Expense | 23.54 | 6.48 | 24.13 | 14.96 | 31.32 |
Earnings From Continuing Operations | 156.73 | 151.89 | 183.06 | 131.99 | 141.32 |
Minority Interest in Earnings | -31.29 | -71.56 | -44.69 | -4.69 | -21.48 |
Net Income | 125.44 | 80.33 | 138.37 | 127.3 | 119.84 |
Net Income to Common | 125.44 | 80.33 | 138.37 | 127.3 | 119.84 |
Net Income Growth | 56.15% | -41.94% | 8.70% | 6.22% | -26.80% |
Shares Outstanding (Basic) | 202 | 201 | 201 | 199 | 200 |
Shares Outstanding (Diluted) | 202 | 201 | 201 | 199 | 200 |
Shares Change (YoY) | 0.74% | 0.15% | 0.82% | -0.42% | 5.03% |
EPS (Basic) | 0.62 | 0.40 | 0.69 | 0.64 | 0.60 |
EPS (Diluted) | 0.62 | 0.40 | 0.69 | 0.64 | 0.60 |
EPS Growth | 55.00% | -42.03% | 7.81% | 6.67% | -30.30% |
Free Cash Flow | 194.19 | 159.14 | 151.96 | 115.92 | 110.33 |
Free Cash Flow Per Share | 0.96 | 0.79 | 0.76 | 0.58 | 0.55 |
Dividend Per Share | - | 0.125 | 0.210 | 0.207 | 0.143 |
Dividend Growth | - | -40.48% | 1.50% | 44.99% | -39.99% |
Gross Margin | 39.48% | 38.85% | 43.62% | 56.97% | 64.65% |
Operating Margin | 14.25% | 7.82% | 10.10% | 9.04% | 10.96% |
Profit Margin | 8.80% | 5.31% | 8.54% | 8.12% | 8.68% |
Free Cash Flow Margin | 13.63% | 10.52% | 9.38% | 7.39% | 7.99% |
EBITDA | 280.11 | 205.3 | 241.03 | 202.87 | 197.6 |
EBITDA Margin | 19.66% | 13.57% | 14.87% | 12.93% | 14.31% |
D&A For EBITDA | 77.02 | 86.93 | 77.39 | 61.1 | 46.36 |
EBIT | 203.09 | 118.37 | 163.64 | 141.77 | 151.25 |
EBIT Margin | 14.25% | 7.82% | 10.10% | 9.04% | 10.96% |
Effective Tax Rate | 13.06% | 4.09% | 11.65% | 10.18% | 18.14% |
Revenue as Reported | - | 1,538 | 1,626 | 1,568 | 1,380 |
Advertising Expenses | - | 146.29 | 251.93 | 526.87 | 585.69 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.